The results of the Cox regression analysis of FGD3 mRNA expression as a continuous variable in five distinct estrogen receptor (ER)–positive breast cancer cohorts are shown in Figure 1A (combined HR, 0.73; 95% CI, 0.64 to 0.82) in which high expression is prognostic of favorable outcome. This evidence concerns the gene FGD3 and breast carcinoma.